Molecular heterogeneity in adjacent cells in triple-negative breast cancer

References

• MengSTripathyDSheteSHer-2 gene amplification can be acquired as breast cancer progressesProc Natl Acad Sci U S A2004101259393939815194824
   PubMed Web of Science ®Google Scholar
• GerlingerMRowanAJHorswellSIntratumor heterogeneity and branched evaluation revealed by multiregion sequencingN Engl J Med201236688389222397650
   PubMed Web of Science ®Google Scholar
• GerlingerMHorswellSLarkinJGenome architecture and evolution of clear cell renal cell carcinoma defined by multiregion sequencingNat Genet20144622523324487277
   PubMed Web of Science ®Google Scholar
• AllisonKSledgeGHeterogeneity and cancerOncology201428977277825224475
   PubMed Web of Science ®Google Scholar
• KleppeMLevineRAssessing the implicationsNat Med20142034234424710377
   PubMed Web of Science ®Google Scholar
• BieseckerLGreenRDiagnostic clinical genome and exome sequencingN Engl J Med20143702418242524941179
   PubMed Web of Science ®Google Scholar
• MalhotraALevineSAllingham-HawkinsAWhole exome sequencing for cancer – is there evidence of clinical utility?Adv Genomics Genet201420115128
   Google Scholar
• UhrJWHuebschmanMLFrenkelEPMolecular profiling of individual tumor cells by hyperspectral microscopic imagingTransl Res201215936637522500509
   PubMed Web of Science ®Google Scholar
• HammondMHayesDDowsettMAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochnemical testing of estrogen and progesterone receptors in breast cancerArch Pathol Lab Med2010134e48e7220586616
   PubMed Web of Science ®Google Scholar
• WolffAHammondMHicksDAmerican Society of Clinical Oncology, College of American PathologistsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline updateJ Clin Oncol2013313997401324101045
   PubMed Web of Science ®Google Scholar
• AllisonKHDintzisSMSchmidtRAFrequency of Her-2 heterogeneity and fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneityAm J Clin Pathol201113686487122095371
   PubMed Web of Science ®Google Scholar
• IsakoffSJTriple negative breast cancer pathologic diagnosis and current chemotherapy treatment optionsEur Oncol Haematol20141013542
   Google Scholar
• FoulkesWDSmithIEReis-FilhoJSTriple-negative breast cancerN Engl J Med20103631938194821067385
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumorsNature200040674775210963602
   PubMed Web of Science ®Google Scholar
• WeigeltBBaehnerFLReis-FilhoJThe contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decadeJ Pathol201022026328019927298
   PubMed Web of Science ®Google Scholar
• SotiriouCPusztaiLGene-expression signatures in breast cancerN Engl J Med200936079080019228622
   PubMed Web of Science ®Google Scholar
• KreikeBvan KouwenhoveMHorlingsHGene expression profiling and histopathological characterization of triple–negative/basal like breast carcinomasBreast Cancer Res20079R6517910759
   PubMed Web of Science ®Google Scholar
• TurnerNLambrosMBHorlingsHMIntegrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene2010292013202320101236
   PubMed Web of Science ®Google Scholar
• MayerIAAbramsonVGLehmannBDPietenpolJANew strategies for triple-negative breast cancer – deciphering the heterogeneityClin Cancer Res201420478279024536073
   PubMed Web of Science ®Google Scholar
• StephensMAEDF statistics for goodness of fit and some comparisonsJ Am Stat Assoc197469730737
   Web of Science ®Google Scholar
• OhiYUmekitaYYoshiokaTAldehyde dehydrogenase expression predicts poor prognosis in triple-negative breast cancerHistopathology20115977678022014057
   PubMed Web of Science ®Google Scholar
• HuAFanCOhDSThe molecular portraits of breast tumors are conserved across microarray platformsBMC Genomics200679616643655
   PubMed Web of Science ®Google Scholar
• PratAAdamoBCheangMCAndersCKCareyLAPerouCMMolecular characterization of basal-like and non-basal-like triple negative breast cancerOncologist20131812313323404817
   PubMed Web of Science ®Google Scholar
• MontagnaEMaisonneuvePRotmenszNHeterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcomeClin Breast Cancer201313313923098574
   PubMed Web of Science ®Google Scholar
• GuedjMMarisaLdeReyniesAA refined molecular taxonomy of breast cancerOncogene2012311196120621785460
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest20111212750276721633166
   PubMed Web of Science ®Google Scholar
• TurnerNCReis-FilhoJSTackling the diversity of triple-negative breast cancerClin Cancer Res201319236380638824298068
   PubMed Web of Science ®Google Scholar
• LiHMaFWangHStem cell marker aldehyde dehydrogenase 1 (ADSH1)-expressing cells are enriched in triple-negative breast cancerInt J Biol Markers201328357364
   Web of Science ®Google Scholar
• CraigDWO’ShaughnessyJAKieferJAGenome and tran-scriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilitiesMol Cancer Ther201312110411623171949
   PubMed Web of Science ®Google Scholar
• de MeloGDGonzalez–AnguloAMTargeting multiple pathways in breast cancerBreast Cancer Manage2014387101
   Google Scholar
• WalerychDNapoliMCollavinLDel SalGThe rebel angel: mutant p53 as the driving oncogene in breast cancerCarcinogenesis2012332007201722822097
   PubMed Web of Science ®Google Scholar
• HartkopfADWallwienerMFehmTNDisseminated tumor cells from the bone marrow of patients with non-metastatic primary breast cancer are predictive of locoregional relapseAnn Oncol20152661155116025791636
   PubMed Web of Science ®Google Scholar